Pascal Deschatelets - 08 Nov 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Chief Scientific Officer
Signature
/s/ David Watson, attorney-in-fact for Pascal Deschatelets
Issuer symbol
APLS
Transactions as of
08 Nov 2022
Net transactions value
-$508,245
Form type
4
Filing time
10 Nov 2022, 07:30:11 UTC
Previous filing
11 Oct 2022
Next filing
12 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Options Exercise $49,395 +18,500 +1.9% $2.67* 975,780 08 Nov 2022 Direct F1
transaction APLS Common Stock Sale $557,640 -12,000 -1.2% $46.47 963,780 08 Nov 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -18,500 -7.7% $0.000000 220,994 08 Nov 2022 Common Stock 18,500 $2.67 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were effected by pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2022.
F2 This stock option was granted on 12/5/2013 and is fully vested.